Cargando…
Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease
BACKGROUND: Lipoprotein(a) (Lp(a)) concentrations are a major independent risk factor for coronary artery disease (CAD) and are mainly determined by variation in LPA. Up to 70% of the LPA coding sequence is located in the hyper-variable kringle IV type 2 (KIV-2) region. It is hardly accessible by co...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613585/ https://www.ncbi.nlm.nih.gov/pubmed/34325833 http://dx.doi.org/10.1016/j.jacc.2021.05.037 |
_version_ | 1783605496716984320 |
---|---|
author | Schachtl-Riess, Johanna F. Kheirkhah, Azin Grüneis, Rebecca Di Maio, Silvia Schoenherr, Sebastian Streiter, Gertraud Losso, Jamie Lee Paulweber, Bernhard Eckardt, Kai-Uwe Köttgen, Anna Lamina, Claudia Kronenberg, Florian Coassin, Stefan |
author_facet | Schachtl-Riess, Johanna F. Kheirkhah, Azin Grüneis, Rebecca Di Maio, Silvia Schoenherr, Sebastian Streiter, Gertraud Losso, Jamie Lee Paulweber, Bernhard Eckardt, Kai-Uwe Köttgen, Anna Lamina, Claudia Kronenberg, Florian Coassin, Stefan |
author_sort | Schachtl-Riess, Johanna F. |
collection | PubMed |
description | BACKGROUND: Lipoprotein(a) (Lp(a)) concentrations are a major independent risk factor for coronary artery disease (CAD) and are mainly determined by variation in LPA. Up to 70% of the LPA coding sequence is located in the hyper-variable kringle IV type 2 (KIV-2) region. It is hardly accessible by conventional technologies, but may contain functional variants. OBJECTIVES: This study sought to investigate the new, very frequent splicing variant KIV-2 4733G>A on Lp(a) and CAD. METHODS: We genotyped 4733G>A in the GCKD (German Chronic Kidney Disease) study (n = 4,673) by allele-specific polymerase chain reaction, performed minigene assays, identified proxy single nucleotide polymorphisms and used them to characterize its effect on CAD by survival analysis in UK Biobank (n = 440,234). Frequencies in ethnic groups were assessed in the 1000 Genomes Project. RESULTS: The 4733G>A variant (38.2% carrier frequency) was found in most isoform sizes. It reduces allelic expression without abolishing protein production, lowers Lp(a) by 13.6 mg/dL (95% CI: 12.5-14.7; P < 0.0001) and is the strongest variance-explaining factor after the smaller isoform. Splicing of minigenes was modified. Compound heterozygosity (4.6% of the population) for 4733G>A and 4925G>A, another KIV-2 splicing mutation, reduces Lp(a) by 31.8 mg/dL and most importantly narrows the interquartile range by 9-fold (from 42.1 to 4.6 mg/dL) when compared to the wild type. In UK Biobank 4733G>A alone and compound heterozygosity with 4925G>A reduced HR for CAD by 9% (95% CI: 7%-11%) and 12% (95% CI: 7%-16%) (both P < 0.001). Frequencies in ethnicities differ notably. CONCLUSIONS: Functional variants in the previously inaccessible LPA KIV-2 region cooperate in determining Lp(a) variance and CAD risk. Even a moderate but lifelong genetic Lp(a) reduction translates to a noticeable CAD risk reduction. (J Am Coll Cardiol 2021;78:437–49) |
format | Online Article Text |
id | pubmed-7613585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
record_format | MEDLINE/PubMed |
spelling | pubmed-76135852022-09-15 Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease Schachtl-Riess, Johanna F. Kheirkhah, Azin Grüneis, Rebecca Di Maio, Silvia Schoenherr, Sebastian Streiter, Gertraud Losso, Jamie Lee Paulweber, Bernhard Eckardt, Kai-Uwe Köttgen, Anna Lamina, Claudia Kronenberg, Florian Coassin, Stefan J Am Coll Cardiol Article BACKGROUND: Lipoprotein(a) (Lp(a)) concentrations are a major independent risk factor for coronary artery disease (CAD) and are mainly determined by variation in LPA. Up to 70% of the LPA coding sequence is located in the hyper-variable kringle IV type 2 (KIV-2) region. It is hardly accessible by conventional technologies, but may contain functional variants. OBJECTIVES: This study sought to investigate the new, very frequent splicing variant KIV-2 4733G>A on Lp(a) and CAD. METHODS: We genotyped 4733G>A in the GCKD (German Chronic Kidney Disease) study (n = 4,673) by allele-specific polymerase chain reaction, performed minigene assays, identified proxy single nucleotide polymorphisms and used them to characterize its effect on CAD by survival analysis in UK Biobank (n = 440,234). Frequencies in ethnic groups were assessed in the 1000 Genomes Project. RESULTS: The 4733G>A variant (38.2% carrier frequency) was found in most isoform sizes. It reduces allelic expression without abolishing protein production, lowers Lp(a) by 13.6 mg/dL (95% CI: 12.5-14.7; P < 0.0001) and is the strongest variance-explaining factor after the smaller isoform. Splicing of minigenes was modified. Compound heterozygosity (4.6% of the population) for 4733G>A and 4925G>A, another KIV-2 splicing mutation, reduces Lp(a) by 31.8 mg/dL and most importantly narrows the interquartile range by 9-fold (from 42.1 to 4.6 mg/dL) when compared to the wild type. In UK Biobank 4733G>A alone and compound heterozygosity with 4925G>A reduced HR for CAD by 9% (95% CI: 7%-11%) and 12% (95% CI: 7%-16%) (both P < 0.001). Frequencies in ethnicities differ notably. CONCLUSIONS: Functional variants in the previously inaccessible LPA KIV-2 region cooperate in determining Lp(a) variance and CAD risk. Even a moderate but lifelong genetic Lp(a) reduction translates to a noticeable CAD risk reduction. (J Am Coll Cardiol 2021;78:437–49) 2021-08-03 /pmc/articles/PMC7613585/ /pubmed/34325833 http://dx.doi.org/10.1016/j.jacc.2021.05.037 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY LICENSE https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Schachtl-Riess, Johanna F. Kheirkhah, Azin Grüneis, Rebecca Di Maio, Silvia Schoenherr, Sebastian Streiter, Gertraud Losso, Jamie Lee Paulweber, Bernhard Eckardt, Kai-Uwe Köttgen, Anna Lamina, Claudia Kronenberg, Florian Coassin, Stefan Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease |
title | Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease |
title_full | Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease |
title_fullStr | Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease |
title_full_unstemmed | Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease |
title_short | Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease |
title_sort | frequent lpa kiv-2 variants lower lipoprotein(a) concentrations and protect against coronary artery disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613585/ https://www.ncbi.nlm.nih.gov/pubmed/34325833 http://dx.doi.org/10.1016/j.jacc.2021.05.037 |
work_keys_str_mv | AT schachtlriessjohannaf frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT kheirkhahazin frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT gruneisrebecca frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT dimaiosilvia frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT schoenherrsebastian frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT streitergertraud frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT lossojamielee frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT paulweberbernhard frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT eckardtkaiuwe frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT kottgenanna frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT laminaclaudia frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT kronenbergflorian frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT coassinstefan frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease AT frequentlpakiv2variantslowerlipoproteinaconcentrationsandprotectagainstcoronaryarterydisease |